← boardnext 2026-08
HELP
Cybin IRL Limiteddistress 5/10 · elevated risk$8.08+3%today-7% from 52w high
Psychiatry / CNS 1
Lead: Major Depressive Disorder · est. market ~$16B (approx, global)
Revenue
pre-revenue
Liquidity
$157M
Runway
1.2 yrs
Shares 1y
-87%
Price & events
+4.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+3.3%
1D
+14.8%
1W
+66.6%
1M
+40.5%
3M
+7.2%
6M
+4.1%
1Y
-27.9%
2Y
-92.9%
5Y
-84.7%
All
Overview
- Market Cap
- $174.54M
- Enterprise Value
- $46.17M
- Volume
- 118.19K
- 52 Week Range
- $3.87 – $8.71
- Total Shares
- 21.60M
- Float Shares
- 99.34M
- % Held by Insiders
- 2.75%
- % Held by Institutions
- 39.85%
- RVOL
- 0.07x
- Beta
- 0.62
Pipeline stages · 2 programs
CYB003
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CYB004
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-10-15 | Phase 3 | CYB003 | Major Depressive Disorder | — | recruiting |
| 2027-03-18 Estimated 50% readout ~2027-06-01 | Phase 3 | CYB003 | Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders, Depression Disorder, Depression | — | recruiting |
| 2028-03-15 Estimated 50% readout ~2028-05-29 | Phase 3 | CYB003 | Major Depressive Disorder | — | enrolling by invitation |
| 2025-10-14 | Phase 2 | CYB004 | Generalized Anxiety Disorder | 36 | active not recruiting |
Catalyst news & presentations · 1
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $38 (+365% upside) · 8 analysts
- 2026-07-09HC Wainwright & Co.Buy
- 2026-07-01Canaccord GenuityBuy
- 2026-04-13TD CowenBuy
- 2026-03-02HC Wainwright & Co.Buy
- 2025-12-03GuggenheimBuy
- 2025-11-20Canaccord GenuityBuy
Competitors — Major Depressive Disorder
- NBIXNEUROCRINE BIOSCIENCES INC$17.2B · D0
- AXSMAxsome Therapeutics, Inc.$12.3B · D0
- XENEXenon Pharmaceuticals Inc.$6.3B · D3
- DFTXDefinium Therapeutics, Inc.$4.7B · D3
- SUPNSUPERNUS PHARMACEUTICALS, INC.$2.7B · D0
- BHVNBiohaven Ltd.$2.2B · D6
- SPTXSeaport Therapeutics, Inc.$1.2B · D1
- ANROAlto Neuroscience, Inc.$937M · D3
- NMRANeumora Therapeutics, Inc.$281M · D5
- TNXPTonix Pharmaceuticals Holding Corp.$170M · D7
Recent news
- 2026-07-22Top Cybin (HELP) Competitors 2026 - MarketBeat
- 2026-07-21Cybin (HELP) Institutional Ownership 2026 $HELP - MarketBeat
- 2026-07-20Chief Financial Officer Greg Cavers Sold A Bunch Of Shares In Cybin - simplywall.st
- 2026-07-20Cybin Inc. (HELP) Q2 2026 Earnings: Wider-than-Expected Loss Despite Positive Stock Reaction - Estimate Uncertainty - dars.gov.et
- 2026-07-17Cybin (HELP) Is Up 6.2% After Advancing HLP003 To Phase 3 And Raising US$50 Million - Yahoo Finance
- 2026-07-17Cybin (HELP) Advances Psychedelic Depression Drug to Phase 3 Amid Fresh Funding – What Really Matters? - Sahm
- 2026-07-13What is HC Wainwright's Forecast for Cybin FY2027 Earnings? - MarketBeat
- 2026-07-10What is HC Wainwright's Estimate for Cybin Q1 Earnings? - MarketBeat
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.